Institutions get together to investigate the pharmaceutical industry, these four pharmaceutical companies said they have received a number of research institutions

 "The plan of the year lies in spring", it is the season of spring in March, when hundreds of flowers are waiting to bloom
.
On this occasion, various research institutions have also launched relevant research work, among which the field of medicine is one of the areas that various institutions pay great attention to
.
Recently, Teyi Pharmaceutical, Baicheng Pharmaceutical, Northland, etc.
have all indicated that they have received investigations from many institutions
.
Teyi Pharmaceuticals Teyi Pharmaceuticals released a record form of investor relations activities on March 17.
The company accepted the investigation of 3 institutional units on March 17, 2022.
The types of institutions are fund companies and securities companies
.
In addition, the company also received two institutional surveys on March 15
.
During the research process, Teyi Pharmaceutical revealed that the comprehensive gross profit rate of the company's proprietary Chinese medicines is above 70%, and Zhikebao tablets are the company's core product, and the gross profit rate has been maintained at above 80%
.
In terms of production capacity, the company has a special production workshop for Zhikebao tablets.
The current production capacity is 1 billion tablets (40 million boxes).
In the later stage, according to market needs, production equipment can be added to existing sites, and the production capacity can reach 2.
4 billion tablets ( equivalent to 100 million boxes)
.
Based on this, in 2022, the company expects to sell 25 million boxes of Zhikebao tablets (about 545 million tablets).
It is expected that in 5-8 years, the annual sales of Zhikebao tablets will reach 2.
4 billion
.
According to the data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines, chemical preparations and chemical raw materials
.
The company's main products include Zhikebao Tablets, Pudilan Anti-inflammatory Tablets, Ganmaoling Granules, Compound Houttuynia Tablets, Pharyngitis Tablets, Xuesaitong Dispersible Tablets, Ginkgo Biloba Dispersible Tablets, Yixinshu Granules, Aluminum Magnesium Carbonate Chewable Tablets, Maple Liaochangweikang Tablets, Omeprazole Enteric-Coated Capsules, Roxithromycin Capsules, Erythromycin Tablets, Levofloxacin Hydrochloride Tablets, Dermatology Xuedu Pills, Yikang Beisong Cream, Children's Cough Syrup, Children's Kechuanling Granules, Jinkui Shenqi Tablets,
etc.
For the two potential varieties of Dermatitis Xuedu Pill and Jiangtangshu Pill, Teyi Pharmaceutical stated in its investor relations activity record form on the 17th that it will actively carry out market promotion
.
The company hopes that through 3 to 5 years of efforts, the skin disease Xuedu Pill and Jiangtangshu Pill will become the core varieties of traditional Chinese medicine with an annual sales revenue of about 300 million yuan.

.
(The performance forecast does not constitute the company's performance commitment to investors, please pay attention to investment risks
.
) Baicheng Pharmaceutical Baicheng Pharmaceutical released news on March 17, 2022-March 16, 2022 morning, the company Received research from Soochow Securities and other institutions
.
Among them, 4 institutions were surveyed on March 15, including 3 securities companies and 1 fund management company
.
Baicheng Pharmaceutical was surveyed by 4 institutions on March 15, 2022
.
Among them, there are 3 securities companies and 1 fund management company
.
Baicheng Pharmaceutical is a comprehensive pharmaceutical R&D enterprise with technology development as its core.
Its main business covers generic drugs and comprehensive R&D services (CRO business), customized R&D and production services (CDMO business), and the quality and efficacy consistency evaluation of generic drugs.
The transformation of R&D technological achievements and the R&D of innovative drugs, etc.
, the service content mainly includes pharmaceutical research, clinical trials, customized production and registration declaration for various pharmaceutical companies and pharmaceutical R&D investment companies
.
In the survey, Baicheng Pharmaceutical stated that the company's research and development expenses increased by 142.
18% over the previous year, and the company's new orders and new orders amounted to 808 million yuan (tax included), a huge increase compared with the same period of the previous year, and also increased research and development.
On the one hand, the company has increased its research and development efforts on various high-end generic drugs and difficult-to-copy drugs, and on the other hand, the company has continued to increase its research and development efforts on innovative drugs
.
The continuous growth of R&D investment provides a strong guarantee for the improvement of the company's technological innovation capability and future performance
.
Sales expenses increased by 244.
59% over the previous year.
The company actively expanded the domestic market, strengthened business team building, and actively participated in various market promotion activities, resulting in a large increase in expenses
.
The company actively expands the domestic market, strengthens business team building, and actively participates in various market promotion activities, resulting in a large increase in expenses
.
According to reports, in the second half of 2021, Baicheng Pharma’s CDMO business achieved external revenue of 9.
4014 million yuan, and provided CDMO business services for the company’s 57 entrusted R&D projects internally.
Double-line expansion and further enhancement of R&D value have laid a solid foundation
.
Northland Northland released an announcement on the company's reception of institutional investors' research on the evening of March 15
.
According to the announcement, Northland received on-site investigations from 12 institutions on March 11, 2022, including Huaan Securities, CITIC Securities, China Galaxy Securities, Jinyuan Securities, Capital Securities, Langmafeng Ventures, Chenming ( Qingdao) Asset Management,
etc.
In the announcement, Northland stated that the NL003 project is quite different from similar drugs under development in response to the NL003 project advantages, NL003 progress and follow-up R&D plans, and the progress of bioengineering new drug industrialization projects that were asked in the institutional survey.
The target gene adopts the self-developed recombinant HGF-X7 gene, which can simultaneously express two HGF isoforms (HGF728 and HGF723) naturally occurring in the human body through alternative splicing after transfection into in vivo cells
.
The NL003 clinical trial has been launched in 24 hospitals.
The company has adjusted the NL003 development plan to "plan to complete a clinical trial for one indication and submit an NDA in 2022-2023".
According to the target plan, it is expected to complete the phase III trial for ulcer adaptation by the end of 2022.
A total of 240 subjects will be enrolled, and relevant subject visits will be completed in the first half of 2023
.
The main body of the bioengineering new drug industrialization project is Beijing Northland Biopharmaceutical Co.
, Ltd.
, a subsidiary of the company, which is currently in the preparatory stage of the start-up procedures
.
According to the data, Northland is an innovative biopharmaceutical enterprise specializing in the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs
.
The company has established core technology platforms such as gene vector construction, engineering bacteria construction, microbial expression, mammalian cell expression, biological preparation production technology and its large-scale production technology, and eye drop drug development, which provides a guarantee for continuous development projects
.
In addition to the above companies, the author also learned that Dizhe Pharmaceuticals has been surveyed by 18 institutions on March 2, 2022
.
Among them, there are 7 fund management companies, 6 investment companies, 3 asset management companies and 1 securities company
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.